Skip to main content
SUTRO BIOPHARMA, INC. logo

SUTRO BIOPHARMA, INC. — Investor Relations & Filings

Ticker · STRO ISIN · US8693671021 LEI · 5493005U6P15VD25P851 US Manufacturing
Open in API
Filings indexed 585 across all filing types
Latest filing 2022-08-08 Interim / Quarterly Rep…
Country US United States of America
Listing US STRO

About SUTRO BIOPHARMA, INC.

https://www.sutrobio.com/

Sutro Biopharma, Inc. is a clinical-stage biotechnology company focused on the discovery, development, and manufacturing of precisely designed cancer therapeutics. The company leverages its proprietary, integrated cell-free protein synthesis platform to create novel antibody-drug conjugates (ADCs). This technology enables the development of next-generation ADCs, including those with single and dual payloads, which are designed to offer improved therapeutic profiles for patients with cancer. Sutro is advancing its own pipeline of clinical-stage product candidates to address areas of significant unmet medical need.

Recent filings

Filing Released Lang Actions
10-Q
Interim / Quarterly Report Q2 2022
2022-08-08 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K current report filed with the SEC, dated August 8, 2022, by Sutro Biopharma, Inc. It announces the issuance of a press release regarding financial results for the quarter ended June 30, 2022. The document itself does not contain the financial results but references an attached press release (Exhibit 99.1). The text explicitly states that the information is being furnished and not filed, and the document is short (3658 characters). This matches the pattern of an Earnings Release announcement within a Form 8-K. Given the nature of the content (announcement of quarterly financial results) and the form type, the best classification is Earnings Release (ER).
2022-08-08 English
8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce significant events. The content describes a milestone payment from Merck to Sutro Biopharma related to a collaboration, which is an update on a financing or capital event. The document is about a specific event rather than a full financial report or earnings release. It is not an annual or quarterly report, nor a call transcript or management report. The milestone payment announcement fits best under Capital/Financing Update (CAP). The document length is about 5,442 characters, which is consistent with a typical 8-K filing. Therefore, the classification is CAP with high confidence.
2022-07-26 English
FORM 4 SUBMISSION
Director's Dealing
2022-07-14 English
Major Shareholding Notification 2022
Major Shareholding Notification
2022-07-08 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated June 27, 2022. It announces the entry into a material definitive agreement (a License and Collaboration Agreement) and updates on a corporate presentation attached as an exhibit. The content focuses on a material contract and an investor presentation update rather than full financial statements or detailed financial analysis. The document is not an earnings release, annual report, or interim report. It is a regulatory filing reporting a significant corporate event and providing an updated presentation. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous SEC filings that do not fit other specific categories.
2022-06-28 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.